Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Phase 1

Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)

NCT07908316 · tracked via the Priya Life Science USA tracker
Sponsor
Phase
Phase 1
Started
2026-11-13
Last updated
2026-11-02

Condition(s) studied

ObesityOverweight

Investigational drug(s) / intervention(s)

Maridebart cafraglutide →

Maridebart cafraglutide: Administered subcutaneously.

Study summary

The primary purpose of the study is to assess the pharmacokinetics of maridebart cafraglutode after switching from weekly GLP-1RA in participants living with overweight or obesity.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * 18 to 70 years of age. * Body Mass Index (BMI) ≥ 25 at screening. * BMI ≥ 23 for Asian participants at screening. * Stable body weight (approximately 5% or less gain or loss) during the 4-week run-in period, unless the study doctor determines otherwise. * Stable dose of weekly GLP-1RA. * Stable gastrointestinal (GI) tolerability. * Contraception for females. * Stable for 3 months if obstructive sleep apnea (OSA), hypertension, hyperlipidemia, and/or hypothyroidism. * Willingness to follow trial procedures for the duration of the trial. Exclusion Criteria: * Type 1/Type 2 diabetes mellitus (DM). * Obesity induced by other endocrine disorder (ex: Cushing's syndrome). * History of malignancy in the last 5 tears except for nonmelanoma skin cancers, cervical, or breast ductal carcinoma in situ. * Acute \& chronic pancreatitis within 1 year. * Uncontrolled thyroid disease. * Gastroparesis or gastric outlet obstruction. * Surgery for obesity in the last 6 months. * Heart attack within 3 months. * History of ischemic optic neuropathy. * Positive HIV or certain positive Hepatitis B or hepatitis C. * Current use of compounded weekly GLP-1RA. * Previous participation in Maridebart cafraglutide trial. * Alcohol or drug abuse. * Pregnancy, breastfeeding, or planning to breastfeed.

Primary outcome measure(s)

  • Area Under the Plasma Concentration-time Curve Over a Dosing Interval (AUCtau) of Maridebart Cafraglutide — Up To 115 days
  • Maximum Observed Plasma Concentration (Cmax) of Maridebart Cafraglutide — Up To 115 days

Trial sites (9)

FacilityCityRegionStatus
Arizona Research Center Phoenix Arizona Recruiting
Catalina Research Institute LLC (CRI) - Montclair Montclair California Recruiting
Fortrea Clinical Research Unit - Daytona Beach Daytona Beach Florida Recruiting
AGA Clinical Trials Hialeah Florida Recruiting
K2 Medical Research Orlando Maitland Florida Recruiting
The Alliance for Multispecialty Research - Lexington Lexington Kentucky Recruiting
Alliance for Multispecialty Research - Knoxville Knoxville Tennessee Recruiting
Fortrea Clinical Research Unit - Dallas Dallas Texas Recruiting
Fortrea Clinical Research Unit Inc. - Madison Madison Wisconsin Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07908316 on ClinicalTrials.gov ↗ ← All trials in the USA